'Best of Times, Worst of Times' -- A Tale for Stem Cell Fans
Highlights:
Sinking stock prices vs. $40 billion market
Profits drive therapies
Test for the California stem cell agency
During the past week, followers of the stem cell world have been treated to sharply contrasting perspectives on the likely success of therapies involving regenerative medicine.
One perspective was bleak; the other robustly optimistic.
One b…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.